Cipla has announced further investment of up to Rs 26 crore in Achira Labs, a company specializing in point-of-care medical test kits. This investment will be made in four tranches, contingent upon the achievement of specific milestones. After the first tranche, Cipla will hold 27.27% of the total voting rights in Achira. This decision follows Cipla's initial acquisition of a 21.05% stake in Achira Labs in June 2022. Achira Labs, based in Bengaluru, focuses on developing and commercializing regulatory-approved medical diagnostic products using microfluidic technology.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.